Abstract | OBJECTIVE: METHOD: This was an institutional review board approved retrospective observational cohort study of 20 patients with POEMS monitored regularly for more than 12 months (median follow-up, 87 months) after treatment onset using our prospectively accumulated database of POEMS from 1999 to 2015. Patients were treated by autologous peripheral blood stem cell transplantation or thalidomide administration. Serum VEGF was measured by ELISA. Outcome measures included clinical and laboratory findings and relapse-free survival. RESULTS: Serum VEGF levels decreased rapidly after treatment, and stabilised by 6 months post treatment. Patients with normalised serum VEGF levels (<1040 pg/mL) at 6 months showed prolonged relapse-free survival (HR=12.81, 95% CI 2.691 to 90.96; p=0.0001) and greater later clinical improvement. The rate of serum VEGF reduction over the first 6 months post treatment correlated with increased grip strength, serum albumin levels, and compound muscle action potential amplitudes at 12 months. CONCLUSIONS:
|
Authors | S Misawa, Y Sato, K Katayama, H Hanaoka, S Sawai, M Beppu, F Nomura, K Shibuya, Y Sekiguchi, Y Iwai, K Watanabe, H Amino, C Ohwada, M Takeuchi, E Sakaida, C Nakaseko, S Kuwabara |
Journal | BMJ open
(BMJ Open)
Vol. 5
Issue 11
Pg. e009157
(Nov 11 2015)
ISSN: 2044-6055 [Electronic] England |
PMID | 26560063
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ |
Chemical References |
- Biomarkers
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Thalidomide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers
(blood)
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- POEMS Syndrome
(blood, therapy)
- Peripheral Blood Stem Cell Transplantation
- Prognosis
- Retrospective Studies
- Thalidomide
(therapeutic use)
- Vascular Endothelial Growth Factor A
(blood)
|